Tetsuo Minamino

Author PubWeight™ 73.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 2007 3.77
2 Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004 3.16
3 Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007 2.48
4 Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res 2008 2.05
5 Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 1.95
6 Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 2003 1.82
7 Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006 1.74
8 AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nat Cell Biol 2010 1.72
9 Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol 2009 1.71
10 Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009 1.63
11 Ablation of C/EBP homologous protein attenuates endoplasmic reticulum-mediated apoptosis and cardiac dysfunction induced by pressure overload. Circulation 2010 1.63
12 A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest 2007 1.61
13 Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005 1.59
14 Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005 1.53
15 Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2005 1.33
16 Long-term stimulation of adenosine A2b receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 2006 1.21
17 PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol 2008 1.20
18 Evaluation of intramitochondrial ATP levels identifies G0/G1 switch gene 2 as a positive regulator of oxidative phosphorylation. Proc Natl Acad Sci U S A 2013 1.02
19 Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 2010 1.01
20 Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004 1.01
21 Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 2008 1.01
22 Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 2004 1.00
23 Long-acting Ca2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 2003 0.99
24 Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 2007 0.97
25 Lamr1 functional retroposon causes right ventricular dysplasia in mice. Nat Genet 2004 0.95
26 Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 2003 0.95
27 Identification of a novel substrate for TNFalpha-induced kinase NUAK2. Biochem Biophys Res Commun 2007 0.95
28 Functional alterations of cardiac proteasomes under physiological and pathological conditions. Cardiovasc Res 2009 0.94
29 Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovasc Res 2006 0.92
30 Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 2004 0.90
31 X-box binding protein 1 regulates brain natriuretic peptide through a novel AP1/CRE-like element in cardiomyocytes. J Mol Cell Cardiol 2010 0.90
32 Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 2006 0.88
33 A role of opening of mitochondrial ATP-sensitive potassium channels in the infarct size-limiting effect of ischemic preconditioning via activation of protein kinase C in the canine heart. Biochem Biophys Res Commun 2005 0.88
34 Protecting endothelial function: A novel therapeutic target of ATP-sensitive potassium channel openers. Cardiovasc Res 2006 0.88
35 Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 2008 0.87
36 Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens Res 2006 0.87
37 S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts. J Mol Cell Cardiol 2007 0.87
38 Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. J Control Release 2011 0.86
39 Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am J Physiol Heart Circ Physiol 2013 0.86
40 A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. Basic Res Cardiol 2010 0.86
41 Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice. Cardiovasc Res 2005 0.85
42 Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc Drugs Ther 2013 0.84
43 Amlodipine ameliorates myocardial hypertrophy by inhibiting EGFR phosphorylation. Biochem Biophys Res Commun 2005 0.84
44 Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J 2012 0.83
45 H(2) mediates cardioprotection via involvements of K(ATP) channels and permeability transition pores of mitochondria in dogs. Cardiovasc Drugs Ther 2012 0.82
46 [Role of endoplasmic reticulum stress in hypertrophic and failing hearts]. Nihon Yakurigaku Zasshi 2005 0.82
47 Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs. J Mol Cell Cardiol 2006 0.82
48 Impaired glucose tolerance: a possible contributor to left ventricular hypertrophy and diastolic dysfunction. Int J Cardiol 2006 0.82
49 A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion. Int J Pharm 2012 0.81
50 Eicosapentaenoic acid reduces myocardial injury induced by ischemia and reperfusion in rabbit hearts. J Cardiovasc Pharmacol 2003 0.81
51 Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 2004 0.81
52 Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J Am Coll Cardiol 2002 0.81
53 Isoform-specific intermolecular disulfide bond formation of heterochromatin protein 1 (HP1). J Biol Chem 2010 0.80
54 The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats. Cardiovasc Drugs Ther 2006 0.80
55 Canine DNA array as a potential tool for combining physiology and molecular biology. Circ J 2003 0.80
56 Identification of p32 as a novel substrate for ATM in heart. Biochem Biophys Res Commun 2007 0.80
57 Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004 0.79
58 Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts. J Cardiovasc Pharmacol 2004 0.79
59 Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. J Mol Cell Cardiol 2004 0.78
60 Ablation of MEK kinase 1 suppresses intimal hyperplasia by impairing smooth muscle cell migration and urokinase plasminogen activator expression in a mouse blood-flow cessation model. Circulation 2005 0.78
61 Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J Control Release 2012 0.78
62 Derivation of a mathematical expression for predicting the time to cardiac events in patients with heart failure: a retrospective clinical study. Hypertens Res 2012 0.78
63 Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 2004 0.77
64 Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 2003 0.76
65 A calcium channel blocker activates both ecto-5(')-nucleotidase and NO synthase in HUVEC. Biochem Biophys Res Commun 2003 0.76
66 New therapeutic application of erythropoietin against ischemic heart diseases. J Pharmacol Sci 2006 0.75
67 Noninvasive and quantitative live imaging reveals a potential stress-responsive enhancer in the failing heart. FASEB J 2014 0.75
68 Erythropoietin, progenitor cells and restenosis. A critique of Stein et al. Thromb Haemost 2012 0.75
69 Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006 0.75
70 [Opening of ATP-sensitive potassium channel attenuates cardiac remodeling induced by chronic inhibition of nitric oxide synthesis]. J Cardiol 2003 0.75
71 Japan expects decrements in both the incidence and mortality of acute myocardial infarction in the modern era: likely or just a dream? Circ J 2010 0.75
72 Signal transduction study using gene-targeted embryonic stem cells. Methods Mol Biol 2003 0.75
73 Decreased mortality associated with statin treatment in patients with acute myocardial infarction and lymphotoxin-alpha C804A polymorphism. Atherosclerosis 2013 0.75
74 Roles of systemic nitric oxide metabolites for human coronary circulation. Cardiovasc Drugs Ther 2004 0.75
75 [The effect of erythropoietin on the improvement of cardiac function in patients with myocardial infarction]. Nihon Rinsho 2011 0.75
76 A calcium channel blocker amlodipine increases coronary blood flow via both adenosine- and NO-dependent mechanisms in ischemic hearts. J Mol Cell Cardiol 2005 0.75